Development and characterization of an indirect ELISA to detect SARS-CoV-2 spike protein-specific antibodies

Krähling, Verena; Halwe, Sandro; Rohde, Cornelius; Becker, Dirk; Berghöfer, Susanne; Dahlke, Christine; Eickmann, Markus; Ercanoglu, Meryem S.; Gieselmann, Lutz; Herwig, Astrid; Kupke, Alexandra; Müller, H.; Neubauer-Rädel, Petra; Klein, Florian; Keller, Christian; Becker, Stephan

doi:10.1016/j.jim.2021.112958

Cited by 34 publications

(32 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For SARS-CoV-2, several studies had reported the use of ELISA to detect antibodies against N protein of SARS-CoV and the sensitivity and specificity of such test ranged from 90 to 94%, and, above 97%, respectively ( Table 11 ) [202] , [203] . Compared to ELISA assay that was aimed to detect antibodies like IgG against the N protein of SARS-CoV-2 [202] , [203] , the use of ELISA test that was focused to detect antibodies against S protein of SARS-CoV-2 showed wide range values of sensitivity and specificity, according to the findings reported from various studies [199] , [204] , [205] , [206] , [207] . Some studies showed that S protein-based ELISA test was less sensitive to detect IgG and IgA against SARS-CoV-2 (<70%) [206] , [207] while few other studies reported that such test was highly sensitive (at least 90%) to detect IgG, IgA, or IgM against the virus S antigen [199] , [204] , [205] , [208] .…”

Section: Different Diagnostic Approaches To Detect Mers-cov and Sars-cov-2 Infectionsmentioning

confidence: 99%

“…Compared to ELISA assay that was aimed to detect antibodies like IgG against the N protein of SARS-CoV-2 [202] , [203] , the use of ELISA test that was focused to detect antibodies against S protein of SARS-CoV-2 showed wide range values of sensitivity and specificity, according to the findings reported from various studies [199] , [204] , [205] , [206] , [207] . Some studies showed that S protein-based ELISA test was less sensitive to detect IgG and IgA against SARS-CoV-2 (<70%) [206] , [207] while few other studies reported that such test was highly sensitive (at least 90%) to detect IgG, IgA, or IgM against the virus S antigen [199] , [204] , [205] , [208] . Therefore, N protein-based ELISA assay could be a better choice of ELISA test to predict serological response in the SARS-CoV-2 patients as the test results of this assay seem to be more consistent and vary less in different reported studies [202] , [203] as compared to the S protein-based ELISA test [199] , [204] , [206] , [207] , [208] , [209] .…”

Section: Different Diagnostic Approaches To Detect Mers-cov and Sars-cov-2 Infectionsmentioning

confidence: 99%

See 1 more Smart Citation

Current diagnostic approaches to detect two important betacoronaviruses: Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Chong

Liew

Ong

et al. 2021

Pathology - Research and Practice

View full text Add to dashboard Cite

Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are two common betacoronaviruses, which are still causing transmission among the human population worldwide. The major difference between the two coronaviruses is that MERS-CoV is now causing sporadic transmission worldwide, whereas SARS-CoV-2 is causing a pandemic outbreak globally. Currently, different guidelines and reports have highlighted several diagnostic methods and approaches which could be used to screen and confirm MERS-CoV and SARS-CoV-2 infections. These methods include clinical evaluation, laboratory diagnosis (nucleic acid-based test, protein-based test, or viral culture), and radiological diagnosis. With the presence of these different diagnostic approaches, it could cause a dilemma to the clinicians and diagnostic laboratories in selecting the best diagnostic strategies to confirm MERS-CoV and SARS-CoV-2 infections. Therefore, this review aims to provide an up-to-date comparison of the advantages and limitations of different diagnostic approaches in detecting MERS-CoV and SARS-CoV-2 infections. This review could provide insights for clinicians and scientists in detecting MERS-CoV and SARS-CoV-2 infections to help combat the transmission of these coronaviruses.

show abstract

Section: Different Diagnostic Approaches To Detect Mers-cov and Sars-cov-2 Infectionsmentioning

confidence: 99%

Section: Different Diagnostic Approaches To Detect Mers-cov and Sars-cov-2 Infectionsmentioning

confidence: 99%

Current diagnostic approaches to detect two important betacoronaviruses: Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Chong

Liew

Ong

et al. 2021

Pathology - Research and Practice

View full text Add to dashboard Cite

show abstract

“…SARS-CoV-2 neutralizing activity of human monoclonal antibodies was investigated based on a previously published protocol with slight modifications (21,65,66). Briefly, monoclonal antibodies were serially diluted in DMEM supplemented with 2% FBS, 1% glutamine and 1% penicillin/streptomycin (Gibco) in 96-well plates before 100 PFU SARS-CoV-2 were added to each sample.…”

Section: Sars-cov-2 Virus Neutralization Test (Vnt100)mentioning

confidence: 99%

Intranasal administration of a monoclonal neutralizing antibody protects mice against SARS-CoV-2 infection

Halwe

Kupke

Vanshylla

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Despite recent availability of vaccines against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), there is an urgent need for specific anti-SARS-CoV-2 drugs. Monoclonal neutralizing antibodies are an important drug class in the global fight against the SARS-CoV-2 pandemic due to their ability to convey immediate protection and their potential to be used as both, prophylactic and therapeutic drugs. Clinically used neutralizing antibodies against respiratory viruses are currently injected intravenously, which can lead to suboptimal pulmonary bioavailability and thus to a lower effectiveness. Here we describe DZIF-10c, a fully human monoclonal neutralizing antibody that binds the receptor-binding domain of SARS-CoV-2 spike protein. DZIF-10c displays an exceptionally high neutralizing potency against SARS-CoV-2 and retains activity against the variants of concern B.1.1.7 and B.1.351. Importantly, not only systemic but also intranasal application of DZIF-10c abolished presence of infectious particles in the lungs of SARS-CoV-2 infected mice and mitigated lung pathology. Along with a favorable pharmacokinetic profile, these results highlight DZIF-10c as a novel human SARS-CoV-2 neutralizing antibody with high in vitro and in vivo antiviral potency. The successful intranasal application of DZIF-10c paves the way for clinical trials investigating topical delivery of anti-SARS-CoV-2 antibodies.

show abstract

“…The preliminary symptoms of coronavirus disease are related to respiratory illness including cough, fever, and difficulty in breathing [ 8 ]. Due to the wide range in severity of the disease many individuals remain asymptomatic or have mild symptoms defining a population that is not tested at the time of acute infection [ 9 ]. The worldwide confirmed cases of COVID-19 are more than 94 million cases and confirmed deaths are more than 2 million cases in the world until March 2021.…”

Section: Introductionmentioning

confidence: 99%

Novel approaches for rapid detection of COVID-19 during the pandemic: A review

Ilkhani

Hedayat

Farhad

2021

Analytical Biochemistry

View full text Add to dashboard Cite

The rapid spread of the SARS-CoV-2 virus that caused the COVID-19 disease, has highlighted our urgent need for sensitive, fast and accurate diagnostic technologies. In fact, one of the main challenges for flatting COVID-19 spread charts is the ability to accurately and rapidly identify asymptomatic cases that result in spreading the virus to close contacts. SARS-CoV-2 virus mutation is also relatively rapid, which makes the detection of COVID-19 diseases still crucial even after the vaccination. Conventional techniques, which are commercially available have focused on clinical manifestation, along with molecular and serological detection tools that can identify the SARS-CoV-2 virus however, owing to various disadvantages including low specificity and sensitivity, a quick, low cost and easy approach is needed for diagnosis of COVID-19. Scientists are now showing extensive interest in an effective portable and simple detection method to diagnose COVID-19. There are several novel methods and approaches that are considered viable advanced systems that can meet the demands. This study reviews the new approaches and sensing technologies that work on COVID-19 diagnosis for easy and successful detection of SARS-CoV-2 virus.

show abstract

Development and characterization of an indirect ELISA to detect SARS-CoV-2 spike protein-specific antibodies

Cited by 34 publications

References 23 publications

Current diagnostic approaches to detect two important betacoronaviruses: Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Current diagnostic approaches to detect two important betacoronaviruses: Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Intranasal administration of a monoclonal neutralizing antibody protects mice against SARS-CoV-2 infection

Novel approaches for rapid detection of COVID-19 during the pandemic: A review

Contact Info

Product

Resources

About